CETUXIMAB vs CISPLATIN<\/p>\n
For head and neck patients chemotherapy can be a difficult experience. The toxicity and permanent effects of such treatment make finding new or alternative drugs a high priority.\u00a0 Current standard care\u00a0 employs cisplatin chemotherapy but recent clinical trials have compared it with a more novel agent, cetuximab.\u00a0 Sadly the results reported so far indicate cisplatin should remain the standard care.\u00a0 It was reported at the European Society of Medical Oncology Congress this month that cetuximab gave inferior outcomes.<\/p>\n
ESMO Press Release<\/a><\/p>\n The Chief Investigator, Professor Hisham Mehanna, can be seen here presenting his findings<\/p>\n Presentation<\/a><\/p>\n The findings have been published in The Lancet and are reported<\/p>\n here<\/a><\/p>\n IMMUNOTHERAPY<\/p>\n Immunotherapies have yielded some encouraging results so far in the treatment of cancer. For head and neck patients they have been used when the cancer is very advanced and treatment options are limited. The benefits seen\u00a0 have led clinicians to now recommend their use at an earlier stage.<\/p>\n Article<\/a><\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" CETUXIMAB vs CISPLATIN For head and neck patients chemotherapy can be a difficult experience. The toxicity and permanent effects of such treatment make finding new or alternative drugs a high priority.\u00a0 Current standard care\u00a0 employs cisplatin chemotherapy but recent clinical trials have compared it with a more novel agent, cetuximab.\u00a0 Sadly the results reported so … Continue reading Head and Neck Research News<\/span>